Difference between revisions of "Amisulpride-Aripiprazole"

From Psychiatrienet
Jump to: navigation, search
Line 3: Line 3:
 
| to = Aripiprazole
 
| to = Aripiprazole
 
| stop = {{Downslweeks}}  
 
| stop = {{Downslweeks}}  
| start = {{Start}}<ref>http://www.emea.europa.eu/humandocs/Humans/EPAR/abilify/abilify</ref>
+
| start = {{Start}} <ref>http://www.emea.europa.eu/humandocs/Humans/EPAR/abilify/abilify</ref>
| info = {{caveQT}}<ref>http://www.ncbi.nlm.nih.gov/pubmed/16096514?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum</ref>
+
| info = {{caveQT}} <ref>http://www.ncbi.nlm.nih.gov/pubmed/16096514?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum</ref>
 +
 
 
| view = StartQuickDownweeks.jpg
 
| view = StartQuickDownweeks.jpg
 
}}
 
}}

Revision as of 09:51, 17 August 2009

Amisulpride
Type Antipsychotic
Group Atypical AP
links
PubChem 2159
PubMed Amisulpride
Wikipedia Amisulpride
Ariprazole
Type Antipsychotic
Group Atypical AP
Other use moodstabilizer
links
EMEA abilify
PubChem 60975
PubMed Ariprazole
Kompas (Dutch) Ariprazole
Wikipedia Ariprazole

Switch medication from Amisulpride to Aripiprazole.[1] [2]

Nietinrijdenbord.png Stop Amisulpride
  • Week 1-3: approx. 75% of initial dose
  • Week 4-6: approx. 50% of initial dose
  • Week 7-9: approx. 25% of initial dose
  • Week 10: stop
Eenrichtingbord.png Start Aripiprazole
  • Day 1: Start drug at target dose [3]
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[4]

[5]

StartQuickDownweeks.jpg
Nietinrijdenbord.png — Amisulpride
Eenrichtingbord.png — Aripiprazole


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. http://www.emea.europa.eu/humandocs/Humans/EPAR/abilify/abilify
  4. Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
  5. http://www.ncbi.nlm.nih.gov/pubmed/16096514?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.